Assessing treatment benefit in the presence of placebo response using the sequential parallel comparison design. (20th February 2022)

• Record Type: Journal Article
• Authors: Liu, Xiaoyan; Kim, Chanmin; Han, Zifei; Lim, Pilar; Roychoudhury, Satrajit; Fava, Maurizio; Doros, Gheorghe
• Is Part Of: Statistics in medicine. Volume 41:Number 12(2022)
• Page Start: 2166
• Page End: 2190
• Publication Date: 2022-02-20
• Subjects: estimand -- placebo response -- principal stratification -- SPCD -- treatment effect; Medical statistics -- Periodicals; Statistique médicale -- Périodiques; Statistiques médicales -- Périodiques; 610.727
• DOI: 10.1002/sim.9349
• Languages: English
• ISSNs: 0277-6715

Abstract

Abstract: In clinical trials, placebo response is considered a beneficial effect arising from multiple factors, including the patient's expectations for the treatment. Its presence makes the classical parallel study design suboptimal and can bias the inference. The sequential parallel comparison design (SPCD), a two‐stage design where the first stage is a classical parallel study design, followed by another parallel design among placebo subjects from the first stage, was proposed to address the shortcomings of the classical design. In SPCD, in lieu of treatment effect, a weighted average of the mean treatment difference in Stage I among all randomized subjects and the mean treatment difference in Stage II among placebo non‐responders was proposed as the efficacy measure. However, by linking two possibly different populations, this weighted average lacks interpretability, and the choice of weight remains controversial. In this work, under the principal stratification framework, we propose a causal estimand for the treatment effect under each of three clinically important principal strata: Always Responders, Never Responders, and Drug‐only Responders. To make the stratum treatment effect identifiable, we introduce a set of assumptions and two sensitivity parameters. By further considering the strata as latent characteristics, the sensitivity parameters can be estimated. An extensive simulation study is conducted to evaluate the operating characteristics of the proposed method. Finally, we apply our method on the ADAPT‐A study data to assess the benefit of low‐dose aripiprazole adjunctive to antidepressant therapy treatment.